Coherus Biosciences, which recently gained its first biosimilar approval for Udenyca, a pegfilgrastim biosimilar referencing Neulasta, has announced that it has signed a 340B prime vendor program contract with Apexus LLC.
Coherus Biosciences, which recently gained its first biosimilar approval for Udenyca, a pegfilgrastim biosimilar referencing Neulasta, has announced that it has signed a 340B prime vendor program contract with Apexus LLC.
Apexus is the Health Resources and Services Administration’s designated prime vendor for the 340B Drug Pricing Program, under which it contracts with nearly all of the 340B-eligible covered entities, and the 340B channel accounts for approximately 35% of the reference pegfilgrastim units sold in the United States.
“Apexus is pleased to be one of Coherus BioSciences’ first partners in the launch of Udenyca,” said Chris Hatwig, president of Apexus, in a statement. “We look forward to working with Coherus in optimizing biosimilar use with this new agreement for Udenyca and to lowering drug pricing while improving patient access.”
Coherus also revealed that it has received a Q code from CMS for Udenyca, and that the code will be active in time for the January launch of Udenyca. With the Q code in place, it will now apply to CMS for transitional pass-through payment status for hospital outpatient settings.
“We continue to progress toward achievement of a robust UDENYCA™ launch on January 3, 2019,” said Denny Lanfear, CEO of Coherus. “The Apexus agreement and [Q code] issuance are [2] important initial components for bringing choice and significant value to patients, payors and providers across the [United States].”
Coherus’ biosimilar was approved in November, making it the second pegfilgrastim biosimilar to gain the FDA’s authorization. First approved was Mylan and Biocon’s Fulphila, which has already launched in the United States. Coherus has said that it will match Mylan’s product on price by discounting its biosimilar by 33% relative to the reference product. Both Udenyca and Fulphila will carry list prices of $4175 per unit.
Global Biosimilar Market Projected to Reach $1.3 Trillion by 2032
April 11th 2024The global biosimilar market is projected to surge from $25.1 billion in 2022 to approximately $1.3 trillion by 2032, with a compound annual growth rate of 17.6%, driven mainly by the increasing prevalence of cancer and the cost-effectiveness of biosimilars, as outlined in a report by Towards Healthcare.
Exploring the Biosimilar Horizon: Julie Reed's Predictions for 2024
February 18th 2024On this episode of Not So Different, Julie Reed, executive director of the Biosimilars Forum, returns to discuss her predictions for the biosimilar industry for 2024 and beyond as well as the impact that the Forum's 4 new members will have on the organization's mission.
Study: More Biosimilar Competition Is Not Lowering Patient OOP Costs
March 29th 2024Despite more biosimilars entering the market and generating significant savings for payers and health care systems, these savings are not resulting in lower out-of-pocket (OOP) costs for patients, according to a recent study.
Biosimilar Business Roundup for October 2023—Podcast Edition
November 5th 2023On this episode, we discuss the biggest news to come out of October 2023, including 3 regulatory approvals, 2 complete response letters, and new data and industry insights that have the potential to impact the entire US biosimilar industry.
Coherus Biosciences Cites Biosimilars as Main Drivers of 2023 Revenue Growth
March 14th 2024In its earnings report for the fourth quarter and full year of 2023, Coherus Biosciences detailed its rising revenue growth, which it partly attributed to increased sales for its pegfilgrastim and ranibizumab biosimilars.